TMDX: The Company Doubling Earnings While Trading at a PEG of 0.53
What if I told you there’s a $4.8B company that...
Grew EPS 100% last year (industry average: 30%) → Beat Q3 consensus by 78% ($0.66 vs $0.37) → Dominates a market growing 8.9% annually through 2030 → Trades at a PEG ratio of 0.53
And most retail investors have never heard of it.
TransMedics (TMDX) has quietly revolutionized organ transplantation. Their Organ Care System keeps donor hearts, lungs, and livers alive outside the body—turning previously unusable organs into lifesaving transplants.
The result? 20.9% market share, up from 13.8% in 2023. And they’re just getting started.
Read our analysis here :
